Posted in | News

Inco Comments on Final and Best Takeover Offer for Falconbridge

Inco Limited (“Inco”) today responded to the announcement by Xstrata plc that it had increased the consideration under its unsolicited offer for Falconbridge Limited.

The Inco Offer for Falconbridge now consists of Cdn.$18.50 in cash and 0.55676 of an Inco common share, assuming full proration of the consideration under the Offer. Assuming the completion of both the Inco Offer and the combination between Inco and Phelps Dodge, and together with the Falconbridge special dividend, Falconbridge shareholders would receive an implied total consideration on a “look-through” basis of Cdn.$64.92 per Falconbridge common share, consisting of approximately: (a) Cdn.$29.77 in cash; and (b) 0.3741 of a Phelps Dodge Inco Corporation common share, valued the closing price of the Phelps Dodge common shares on the New York Stock Exchange and applicable U.S.-Canadian dollar exchange rates on July 19, 2006. This is $1.67 more than the value of the Xstrata offer of $63.25 per share, including the Falconbridge special dividend.

“This is our best and final offer for Falconbridge”, said Mr. Hand. “It provides greater value than the competing offer from Xstrata, and it is available for acceptance only until midnight (Vancouver time) on Thursday, July 27. Xstrata’s competing offer remains subject to a variety of conditions, including Investment Canada approval and shareholder approval, and will not be available for acceptance until at least August 14.

“Only Inco’s Offer gives both current Inco and Falconbridge shareholders the opportunity to participate in the earnings, cash flow and growth potential of Phelps Dodge Inco. For these reasons and others, we strongly encourage Falconbridge shareholders to tender their shares to Inco’s increased Offer,” he said.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.